Four-year clinical update and treatment switching-adjusted outcomes with first-line nivolumab plus ipilimumab with chemotherapy for metastatic non-small cell lung cancer in the CheckMate 9LA randomized trial

David P. Carbone,Tudor-Eliade Ciuleanu,Michael Schenker,Manuel Cobo,Stéphanie Bordenave,Oscar Juan-Vidal,Juliana Menezes,Niels Reinmuth,Eduardo Richardet,Ying Cheng,Hideaki Mizutani,Enriqueta Felip,Bogdan Zurawski,Aurelia Alexandru,Luis Paz-Ares,Shun Lu,Thomas John,Xiaoqing Zhang,Javed Mahmood,Nan Hu,Tuli De,Irene Santi,John R. Penrod,Yong Yuan,Adam Lee,Martin Reck

DOI: https://doi.org/10.1136/jitc-2023-008189

IF: 12.469

2024-02-01

Journal for ImmunoTherapy of Cancer

Abstract:Background In CheckMate 9LA, nivolumab plus ipilimumab with chemotherapy prolonged overall survival (OS) versus chemotherapy regardless of tumor PD-L1 expression or histology. We report updated efficacy and safety in all randomized patients with a minimum 4-year follow-up and an exploratory treatment-switching adjustment analysis in all treated patients who received chemotherapy and subsequent immunotherapy. Methods Adults with stage IV/recurrent non-small cell lung cancer (NSCLC), no sensitizing EGFR/ALK alterations, and ECOG performance status ≤1 were randomized 1:1 to nivolumab 360 mg every 3 weeks plus ipilimumab 1 mg/kg every 6 weeks with chemotherapy (two cycles) or chemotherapy (four cycles, with optional maintenance pemetrexed for the nonsquamous population). Assessments included OS, progression-free survival, and objective response rate. Exploratory analyses included efficacy by tumor PD-L1 expression and histology and in patients who discontinued nivolumab plus ipilimumab with chemotherapy due to treatment-related adverse events (TRAEs), and a treatment-switching adjustment analysis using inverse probability of censoring weighting. Results With a 47.9-month minimum follow-up for OS, nivolumab plus ipilimumab with chemotherapy continued to prolong OS over chemotherapy in all randomized patients (HR 0.74, 95% CI 0.63 to 0.87; 4-year OS rate: 21% versus 16%), regardless of tumor PD-L1 expression (HR (95% CI): PD-L1<1%, 0.66 (0.50 to 0.86) and ≥1%, 0.74 (0.60 to 0.92)) or histology (squamous, 0.64 (0.48 to 0.84) and non-squamous, 0.80 (0.66 to 0.97)). In patients who discontinued all components of nivolumab plus ipilimumab with chemotherapy due to TRAEs (n=61), the 4-year OS rate was 41%. With treatment-switching adjustment for the 36% of patients receiving subsequent immunotherapy in the chemotherapy arm, the estimated HR of nivolumab plus ipilimumab with chemotherapy versus chemotherapy was 0.66 (95% CI 0.55 to 0.80). No new safety signals were observed. Conclusions In this 4-year update, patients treated with nivolumab plus ipilimumab with chemotherapy continued to have long-term, durable efficacy benefit over chemotherapy regardless of tumor PD-L1 expression and/or histology. A greater estimated relative OS benefit was observed after adjustment for subsequent immunotherapy use in the chemotherapy arm. These results further support nivolumab plus ipilimumab with chemotherapy as a first-line treatment for patients with metastatic/recurrent NSCLC, including those with tumor PD-L1<1% or squamous histology, populations with high unmet needs.

oncology,immunology

What problem does this paper attempt to address?

This paper aims to address the issue of long - term survival benefit in non - small - cell lung cancer (NSCLC) patients during first - line treatment, especially for those patient groups with low tumor PD - L1 expression levels (<1%) or squamous histology features. Specifically, the study updated the efficacy and safety data through four - year clinical follow - up, evaluated the long - term survival benefit of the nivolumab plus ipilimumab combined chemotherapy regimen relative to chemotherapy alone, and conducted a treatment - switch adjustment analysis for patients receiving subsequent immunotherapy to reduce the impact of potential bias. These results further support nivolumab plus ipilimumab combined chemotherapy as a first - line treatment option for patients with metastatic or recurrent NSCLC, especially for those patient groups with highly unmet needs, such as tumor PD - L1 expression <1% or squamous histology features.